Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia

Trial Profile

Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Head and neck cancer; Leucoplakia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2010 Status changed from active, no longer recruiting to completed as reported by
    • 24 Sep 2010 Actual end date (Apr 2010) added as reported by
    • 24 Jun 2008 Additional trial identifier MDA2005-0485 reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top